Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Phoenician Capital John G. Khabbaz | “HALO licenses a technology, ENHANZE®, that allows large pharmaceutical companies to replace hours on an IV drip for a quick shot under the skin. The technology works by injecting an enzyme that temporarily clears a natural gel-like barrier under the skin, letting a large volume of drug spread and absorb fast enough to replace the drip. HALO does not make drugs itself; it licenses the technology and collects fees and royalties on every dose of an approved partner drug sold worldwide, more like a toll road than a drug company. Once a partner's drug is approved using Halozyme's technology, switching to a competitor would mean spending years re-running clinical trials, which most partners won't do. The most material risk in the HALO investment is patent cliff exposure: core ENHANZE patents expire between 2027 and 2034 depending on jurisdiction, and management is working to extend the royalty runway toward the 2040s before that window closes. Separately, and more speculatively, Merck has launched a competing product without paying Halo a royalty, and though Halo won a German infringement injunction against Merck, we do not believe that a final ruling will go in Halo's favor. This dispute rests on a separate, newer patent family, not the ENHANZE patents licensed to Halo's partners. While not our base case, a HALO win, even if partial, could add a royalty on one of the world's best-selling Merck drugs. Separately, Halo licensed ENHANZE in December to Skye Bioscience to co-formulate Skye's obesity drug candidate for subcutaneous delivery in combination with a GLP-1 obesity drug. The drug is still in early trials, with the next study only starting in mid-2026, but Halo would earn payments and a royalty on any future sales, so this is optionality, not something we're underwriting. Over the past five years, Halo generated approximately $2 billion in free cash flow and reinvested approximately $2 billion in acquisitions that are expected to generate additional revenue in the future but haven't yet. Today, the company generates roughly three times the revenue of five years ago, with earnings roughly unchanged, because the acquisitions haven't yet scaled into the operating leverage built into the model. As they do, we expect earnings to catch up to revenue. We built the position at a meaningful discount to what we think the business is worth, and only about half of that value depends on the distant future, a healthier mix than is typical this early in building out a royalty business.” | NEUTRAL | Q2 2026 Jul 21, 2026 | View Pitch |
Meridian Growth Fund ArrowMark Colorado Holdings, LLC | “Halozyme Therapeutics, Inc. is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous infusions into quick injections delivered in minutes. The technology reduces treatment burden for patients and alleviates capacity constraints for healthcare providers. Halozyme reported a strong quarter, with royalty revenues up 65% and continued uptake of its drugs, along with expanding use-case indications from its pharmaceutical partners. Management raised full-year guidance for both revenues and earnings, which was well-received by investors. During the period, we trimmed our position as the share price appreciated, consistent with our disciplined valuation approach. :contentReference[oaicite:14]{index=14} BSD Analysis: HALO's high-margin royalty model compounds with partner uptake; ENHANZE is a sticky platform. Guidance raises and pipeline breadth support earnings visibility; FCF conversion is excellent. Pullbacks offer add points.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Meridian Growth Fund ArrowMark Colorado Holdings, LLC | “Halozyme Therapeutics, Inc. is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous (IV) infusions into quick injections that can be delivered in just minutes. Shares of Halozyme declined during the period following news that the Centers for Medicare & Medicaid Services (CMS) may reconsider how it classifies reformulated drugs using ENHANZE. Under the proposed change, such formulations may no longer qualify as “new drugs,” potentially subjecting them to Medicare price negotiations earlier than previously expected. While the proposal remains under review, we believe ENHANZE continues to offer meaningful advantages… We slightly reduced our position in the company during the quarter. BSD Analysis: Despite platform strength and widespread pharma partnerships, Halozyme faces reimbursement overhang risk that could compress long-term royalty economics. The company's high-margin royalty model supports strong cash generation, but CMS rule changes may lower future uptake or pricing. Shares trade below intrinsic NPV of partnerships, with upside tied to regulatory clarity and pipeline expansion.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
